Investors Sell Gilead Sciences (GILD) on Strength on Analyst Downgrade
Investors sold shares of Gilead Sciences, Inc. (NASDAQ:GILD) on strength during trading on Wednesday after ValuEngine downgraded the stock from a hold rating to a sell rating. $82.18 million flowed into the stock on the tick-up and $112.78 million flowed out of the stock on the tick-down, for a money net flow of $30.60 million out of the stock. Of all stocks tracked, Gilead Sciences had the 0th highest net out-flow for the day. Gilead Sciences traded up $0.54 for the day and closed at $65.94
A number of other brokerages have also recently weighed in on GILD. Raymond James cut their price objective on shares of Gilead Sciences from $90.00 to $85.00 and set a “strong-buy” rating on the stock in a research note on Tuesday. BidaskClub cut shares of Gilead Sciences from a “buy” rating to a “hold” rating in a research note on Wednesday, October 24th. Piper Jaffray Companies cut shares of Gilead Sciences from an “overweight” rating to a “neutral” rating and cut their price objective for the company from $85.00 to $75.00 in a research note on Friday, October 26th. Morgan Stanley lifted their price objective on shares of Gilead Sciences from $85.00 to $86.00 and gave the company an “equal weight” rating in a research note on Wednesday, December 19th. Finally, Evercore ISI restated a “buy” rating on shares of Gilead Sciences in a research note on Wednesday, October 31st. Two analysts have rated the stock with a sell rating, nine have issued a hold rating, nine have assigned a buy rating and two have given a strong buy rating to the stock. The company presently has a consensus rating of “Buy” and an average target price of $84.01.
In other Gilead Sciences news, Director John C. Martin sold 50,000 shares of the business’s stock in a transaction dated Monday, December 3rd. The shares were sold at an average price of $71.20, for a total value of $3,560,000.00. Following the sale, the director now directly owns 2,877,762 shares in the company, valued at $204,896,654.40. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. 1.16% of the stock is currently owned by insiders.
The company has a market capitalization of $87.28 billion, a price-to-earnings ratio of 10.72, a PEG ratio of 66.65 and a beta of 1.19. The company has a debt-to-equity ratio of 1.09, a current ratio of 3.36 and a quick ratio of 3.29.
Gilead Sciences (NASDAQ:GILD) last issued its quarterly earnings results on Monday, February 4th. The biopharmaceutical company reported $1.44 earnings per share for the quarter, missing the Zacks’ consensus estimate of $1.70 by ($0.26). The company had revenue of $5.80 billion during the quarter, compared to analysts’ expectations of $5.52 billion. Gilead Sciences had a return on equity of 37.03% and a net margin of 24.65%. The company’s revenue for the quarter was down 2.6% compared to the same quarter last year. During the same period in the prior year, the business posted $1.78 EPS. As a group, sell-side analysts anticipate that Gilead Sciences, Inc. will post 6.23 earnings per share for the current year.
The business also recently declared a quarterly dividend, which will be paid on Thursday, March 28th. Investors of record on Friday, March 15th will be paid a $0.63 dividend. The ex-dividend date of this dividend is Thursday, March 14th. This represents a $2.52 dividend on an annualized basis and a yield of 3.82%. This is a boost from Gilead Sciences’s previous quarterly dividend of $0.57. Gilead Sciences’s dividend payout ratio (DPR) is currently 37.07%.
COPYRIGHT VIOLATION WARNING: This news story was first published by Watch List News and is the property of of Watch List News. If you are viewing this news story on another publication, it was stolen and reposted in violation of United States & international copyright and trademark law. The legal version of this news story can be accessed at https://www.watchlistnews.com/investors-sell-gilead-sciences-gild-on-strength-on-analyst-downgrade/2819033.html.
Gilead Sciences Company Profile (NASDAQ:GILD)
Gilead Sciences, Inc discovers, develops, and commercializes therapeutics in the areas of unmet medical needs in the United States, Europe, and internationally. The company's products include Biktarvy, Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Atripla, Truvada, Viread, Emtriva, and Tybost for the treatment of human immunodeficiency virus (HIV) infection in adults; and Vosevi, Vemlidy, Epclusa, Harvoni, Sovaldi, Viread, and Hepsera products for treating liver diseases.
Recommended Story: Trading Ex-Dividend Strategy
Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.